- Home
- AUPH vs MNKD Comparison
AUPH vs MNKD Comparison
Compare AUPH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- MNKD
- Stock Information
- Founded
- AUPH 1993
- MNKD 1991
- Country
- AUPH Canada
- MNKD United States
- Employees
- AUPH N/A
- MNKD N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- MNKD Health Care
- Exchange
- AUPH Nasdaq
- MNKD Nasdaq
- Market Cap
- AUPH 1.6B
- MNKD 1.7B
- IPO Year
- AUPH 1999
- MNKD 2004
- Fundamental
- Price
- AUPH $12.54
- MNKD $5.28
- Analyst Decision
- AUPH Strong Buy
- MNKD Strong Buy
- Analyst Count
- AUPH 2
- MNKD 5
- Target Price
- AUPH $13.00
- MNKD $10.80
- AVG Volume (30 Days)
- AUPH 1.2M
- MNKD 4.4M
- Earning Date
- AUPH 11-10-2025
- MNKD 11-05-2025
- Dividend Yield
- AUPH N/A
- MNKD N/A
- EPS Growth
- AUPH N/A
- MNKD 149.32
- EPS
- AUPH 0.42
- MNKD 0.11
- Revenue
- AUPH $260,111,000.00
- MNKD $301,736,000.00
- Revenue This Year
- AUPH $17.33
- MNKD $14.78
- Revenue Next Year
- AUPH $14.31
- MNKD $19.36
- P/E Ratio
- AUPH $30.05
- MNKD $48.98
- Revenue Growth
- AUPH 25.59
- MNKD 21.48
- 52 Week Low
- AUPH $6.55
- MNKD $3.38
- 52 Week High
- AUPH $13.54
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- AUPH 60.86
- MNKD 48.16
- Support Level
- AUPH $11.48
- MNKD $5.21
- Resistance Level
- AUPH $12.70
- MNKD $5.62
- Average True Range (ATR)
- AUPH 0.34
- MNKD 0.21
- MACD
- AUPH 0.13
- MNKD -0.03
- Stochastic Oscillator
- AUPH 89.64
- MNKD 59.04
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.